19,653 Shares in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Acquired by Bryce Point Capital LLC

Bryce Point Capital LLC purchased a new position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 19,653 shares of the company’s stock, valued at approximately $438,000.

Several other hedge funds have also made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock worth $80,000 after purchasing an additional 596 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $50,000. National Bank of Canada FI bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $51,000. Geode Capital Management LLC lifted its holdings in shares of NewAmsterdam Pharma by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 88,544 shares of the company’s stock worth $2,276,000 after purchasing an additional 2,222 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of NewAmsterdam Pharma by 12.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,028 shares of the company’s stock worth $451,000 after purchasing an additional 2,439 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $23.60 on Monday. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.29. The stock has a market cap of $2.65 billion, a PE ratio of -12.55 and a beta of -0.03. The business’s fifty day moving average is $19.80 and its 200-day moving average is $20.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. The firm had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. Equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on NAMS shares. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an “overweight” rating and a $42.00 target price on the stock. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a “neutral” rating and a $27.00 target price on the stock. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, July 5th. Finally, Stifel Nicolaus began coverage on NewAmsterdam Pharma in a research note on Tuesday, June 10th. They set a “buy” rating and a $44.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.30.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, Director James N. Topper bought 8,584 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were acquired at an average cost of $19.50 per share, for a total transaction of $167,388.00. Following the acquisition, the director directly owned 3,022,153 shares of the company’s stock, valued at $58,931,983.50. The trade was a 0.28% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Douglas F. Kling sold 100,000 shares of NewAmsterdam Pharma stock in a transaction on Monday, June 16th. The stock was sold at an average price of $19.29, for a total value of $1,929,000.00. Following the completion of the transaction, the chief operating officer owned 44,000 shares in the company, valued at $848,760. The trade was a 69.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 12,364 shares of company stock worth $236,839 and have sold 198,612 shares worth $4,025,887. 20.84% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.